These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 11599634)

  • 1. How well tolerated are lipid-lowering drugs?
    Tomlinson B; Chan P; Lan W
    Drugs Aging; 2001; 18(9):665-83. PubMed ID: 11599634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overcoming toxicity and side-effects of lipid-lowering therapies.
    Wilkinson MJ; Laffin LJ; Davidson MH
    Best Pract Res Clin Endocrinol Metab; 2014 Jun; 28(3):439-52. PubMed ID: 24840269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment.
    Chatzizisis YS; Koskinas KC; Misirli G; Vaklavas C; Hatzitolios A; Giannoglou GD
    Drug Saf; 2010 Mar; 33(3):171-87. PubMed ID: 20158283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statin-fibrate combination therapy.
    Shek A; Ferrill MJ
    Ann Pharmacother; 2001; 35(7-8):908-17. PubMed ID: 11485144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statin-associated myopathy.
    Hamilton-Craig I
    Med J Aust; 2001 Nov; 175(9):486-9. PubMed ID: 11758079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DPP-4 Inhibitors in Combination with Lipid-Lowering Agents and Risk of Serious Muscular Injury: A Nested Case-Control Study in a Nationwide Cohort of Patients with Type 2 Diabetes Mellitus.
    Pariente A; Labat V; Mansiaux Y; Salvo F; Bégaud B; Raschi E; Faillie JL; Létinier L; Bezin J
    Drug Saf; 2020 Aug; 43(8):767-774. PubMed ID: 32306223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk for myopathy with statin therapy in high-risk patients.
    Ballantyne CM; Corsini A; Davidson MH; Holdaas H; Jacobson TA; Leitersdorf E; März W; Reckless JP; Stein EA
    Arch Intern Med; 2003 Mar; 163(5):553-64. PubMed ID: 12622602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statin safety: an overview and assessment of the data--2005.
    Bays H
    Am J Cardiol; 2006 Apr; 97(8A):6C-26C. PubMed ID: 16581330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid-lowering drug use and cardiovascular events after myocardial infarction.
    Klungel OH; Heckbert SR; de Boer A; Leufkens HG; Sullivan SD; Fishman PA; Veenstra DL; Psaty BM
    Ann Pharmacother; 2002 May; 36(5):751-7. PubMed ID: 11978147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myopathy due to statin/fibrate use in the Netherlands.
    Mantel-Teeuwisse AK; Klungel OH; Herings RM; van Puijenbroek EP; Porsius AJ; de Boer A
    Ann Pharmacother; 2002 Dec; 36(12):1957-60. PubMed ID: 12452761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia.
    Kostapanos MS; Milionis HJ; Elisaf MS
    Am J Cardiovasc Drugs; 2010; 10(1):11-28. PubMed ID: 20104931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse effects of statins - mechanisms and consequences.
    Bełtowski J; Wójcicka G; Jamroz-Wiśniewska A
    Curr Drug Saf; 2009 Sep; 4(3):209-28. PubMed ID: 19534648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The combinations of statins and fibrates: pharmacokinetic and clinical implications].
    González Santos P
    Clin Investig Arterioscler; 2014 Jul; 26 Suppl 1():7-11. PubMed ID: 25043540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statin-induced myopathy: a review and update.
    Abd TT; Jacobson TA
    Expert Opin Drug Saf; 2011 May; 10(3):373-87. PubMed ID: 21342078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Fibrate and statine myopathy].
    Finsterer J
    Nervenarzt; 2003 Feb; 74(2):115-22. PubMed ID: 12596012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety issues with statin therapy.
    Talbert RL
    J Am Pharm Assoc (2003); 2006; 46(4):479-88; quiz 488-90. PubMed ID: 16913392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current overview of statin-induced myopathy.
    Rosenson RS
    Am J Med; 2004 Mar; 116(6):408-16. PubMed ID: 15006590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An overview of statin-induced myopathy and perspectives for the future.
    Nikolic D; Banach M; Chianetta R; Luzzu LM; Pantea Stoian A; Diaconu CC; Citarrella R; Montalto G; Rizzo M
    Expert Opin Drug Saf; 2020 May; 19(5):601-615. PubMed ID: 32233708
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of HMG-CoA reductase inhibitors on skeletal muscle: are all statins the same?
    Evans M; Rees A
    Drug Saf; 2002; 25(9):649-63. PubMed ID: 12137559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.